Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)

Inge Winter-van Rossum(University Medical Center Utrecht), Peter Haddad(Deakin University), Aurel Nireştean, Timo Schurr(Innsbruck Medical University), Nikos Stefanis(National and Kapodistrian University of Athens), Georg Psota, Mark Weiser(The University of Queensland), Jurjen J. Luykx(Utrecht University), Alex Hofer(Semmelweis University), István Bitter(Semmelweis University), Marcin Olajossy, Ramin Nilforooshan(University of Surrey), René S. Kahn(Icahn School of Medicine at Mount Sinai), Silvana Galderisi(University of Campania "Luigi Vanvitelli"), Adela Magdalena Ciobanu(Carol Davila University of Medicine and Pharmacy), Marina Kupchik(Tel Aviv University), Birte Glenthøj(University of Copenhagen), Erik Johnsen, Csekey László, Lucho G Hranov, Solveig Klebo Reitan, Michael Davidson(Amsterdam University College), Mor Bar Haim(Sheba Medical Center), Alexander Teitelbaum(Hebrew University of Jerusalem), M.D. Mosescu(Utrecht University), Julio Bobes(Universidad de Oviedo), Claudia Leucht(University of Illinois Chicago), Alessandro Rossi(University of L'Aquila), Alkomiet Hasan(University of Augsburg), Joachim Cordes(Heinrich Heine University Düsseldorf), Georg Kemmler(Innsbruck Medical University), Stefan Leucht(TUM Klinikum), Walter Wolfgang Fleischhacker(Innsbruck Medical University), Manuel Morrens(University of Antwerp)
The Lancet Psychiatry
January 27, 2023
Cited by 48


Related Papers